Endocyte, Inc. (ECYT) VP Sells $117,084.24 in Stock
Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 23,231 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the completion of the sale, the vice president now directly owns 150,579 shares of the company’s stock, valued at $758,918.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Endocyte, Inc. (ECYT) traded down $0.25 during trading on Thursday, hitting $4.66. 846,700 shares of the stock were exchanged, compared to its average volume of 1,175,467. Endocyte, Inc. has a twelve month low of $1.17 and a twelve month high of $6.55.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The firm had revenue of $0.03 million for the quarter. During the same quarter last year, the business posted ($0.21) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. research analysts predict that Endocyte, Inc. will post -1.24 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in Endocyte by 34.1% during the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the period. Spark Investment Management LLC acquired a new position in Endocyte during the second quarter worth about $177,000. LMR Partners LLP acquired a new position in Endocyte during the second quarter worth about $196,000. Bank of New York Mellon Corp grew its position in Endocyte by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares during the period. Finally, Renaissance Technologies LLC grew its position in Endocyte by 284.4% during the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares during the period. Institutional investors and hedge funds own 17.68% of the company’s stock.
A number of equities research analysts have recently commented on ECYT shares. Zacks Investment Research cut shares of Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised shares of Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. Finally, Cowen reiterated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd.
Endocyte Company Profile
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.